Sugi Predict

Sugi Predict / Targets / STARD3

STARD3

StAR-related lipid transfer protein 3 · Q14849 · STARD3 on Sugi Atlas →

28 patent compounds predicted against STARD3, 17 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3053501 SCHEMBL3053501 0.55 1/20
SCHEMBL721339 SCHEMBL721339 0.52 1/20
SCHEMBL5226852 SCHEMBL5226852 0.52 1/20
SCHEMBL14107496 SCHEMBL14107496 0.52 1/20
SCHEMBL4871477 SCHEMBL4871477 0.50 1/20
SCHEMBL4864912 SCHEMBL4864912 0.49 1/20
SCHEMBL14086093 SCHEMBL14086093 0.49 1/20
SCHEMBL19616715 SCHEMBL19616715 0.46 1/20
SCHEMBL172838 SCHEMBL172838 0.46 1/20
SCHEMBL19959258 SCHEMBL19959258 0.46 1/20
SCHEMBL29486422 SCHEMBL29486422 0.46 1/20
SCHEMBL1550311 SCHEMBL1550311 0.45 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL3188334) 0.44 1/20
SCHEMBL6766529 SCHEMBL6766529 0.43 1/20
SCHEMBL25207908 SCHEMBL25207908 0.42 1/20
SCHEMBL31247846 SCHEMBL31247846 0.42 1/20
SCHEMBL4179970 SCHEMBL4179970 0.42 1/20

Clinical trials — most relevant to STARD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pharmacological Regulation of Fat Transport in Metabolic Syndrome PHASE4COMPLETED
Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment PHASE4COMPLETED
The HDL Particle Protection Study PHASE4COMPLETED
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) PHASE3COMPLETED
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis EARLY_PHASE1COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Association of Genetic Polymorphisms With Lipid Lowering Effects of Statin Therapy nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Omega 3 and Fibre Intervention Study to Improve Metabolic Health nanUNKNOWN
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Abnormal Lipids - Causes and Effects nanRECRUITING
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction nanUNKNOWN
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
The Combined Effect of Omega-3 Fatty Acid and Vitamin D3 on Lipid Profile Levels and Oxidized Low Density Lipoprotein nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a STARD3 binder may also engage these)

ProteinNameSimilarity
Q61542 — 1.000 Q61542 →
F7B909 — 1.000 F7B909 →
Q9DFS4 — 1.000 Q9DFS4 →
Q92503 — 0.986 Q92503 →
Q5SNQ7 — 0.982 Q5SNQ7 →
P0CI65 — 0.982 P0CI65 →
Q66K14 — 0.981 Q66K14 →
O43304 — 0.981 O43304 →
Q3U213 — 0.980 Q3U213 →
P49675 — 0.980 P49675 →
E9PUQ8 — 0.980 E9PUQ8 →
Q6PJI9 — 0.979 Q6PJI9 →
P79245 — 0.979 P79245 →
A8Y5H7 — 0.979 A8Y5H7 →
Q9DEB4 — 0.979 Q9DEB4 →
P70114 — 0.979 P70114 →
O95772 — 0.979 O95772 →
Q8VCZ6 — 0.979 Q8VCZ6 →
O02697 — 0.979 O02697 →
Q0V9N0 — 0.979 Q0V9N0 →
Q5XHF8 — 0.978 Q5XHF8 →
Q90ZB9 — 0.978 Q90ZB9 →
A2VE70 — 0.978 A2VE70 →
G5EF51 — 0.978 G5EF51 →
Q96JX3 — 0.978 Q96JX3 →
Q5SVR0 — 0.978 Q5SVR0 →
DNM2 Dynamin-2 0.978 landscape →
Q6WQJ1 — 0.978 Q6WQJ1 →
Q9WTZ2 — 0.978 Q9WTZ2 →
Q28996 — 0.978 Q28996 →